This is an attractive hypothesis, since their much stronger effects on BCR/ABL (when compared to imatinib) fail to explain their excellent clinical efficacy, as CML LSC are considered to survive independent of BCR/ABL [352,353]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.